| |
Smiths Group confirms approach for medical unit Friday, May 31, 2013 12:13 AM PDT LONDON (Reuters) - British engineering company Smiths Group said on Friday it had received an approach for its medical division, which sources have said could be worth more than 2 billion pounds. The company confirmed in a statement that it was in early stage talks about a disposal following reports on Thursday that it had begun investigating a sale after an approach from U.S. healthcare group CareFusion. Smiths Medical, which contributed 35 percent of the company's operating profit last year, supplies equipment to hospitals and emergency services. ... Full Story | Top |
Immunotherapy is not just for melanoma anymore Thursday, May 30, 2013 10:08 PM PDT By Julie Steenhuysen and Deena Beasley CHICAGO/LOS ANGELES (Reuters) - Diagnosed with advanced lung cancer over a year ago, Gabe Tartaglia was loath to undergo the kind of harsh chemotherapy that had devastated his sister before her death three years earlier from pancreatic cancer. He decided to enter a clinical trial for a new drug designed to trigger the immune system to fight cancer. The results were better than anyone expected. ... Full Story | Top |
Sharks worth more for tourism than in soup: study Thursday, May 30, 2013 05:49 PM PDT | Top |
Trip to Mars would likely exceed radiation limits for astronauts Thursday, May 30, 2013 05:00 PM PDT | Top |
UK cost agency recommends Bayer, Regeneron eye drug Thursday, May 30, 2013 04:28 PM PDT LONDON (Reuters) - Britain's healthcare cost watchdog NICE is recommending a new eye drug from Bayer and Regeneron, after a price discount was offered for its use on the state health service. The draft decision by the National Institute for Health and Clinical Excellence (NICE) means Eylea will compete in Britain with Novartis's established product Lucentis as a treatment for wet age-related macular degeneration (AMD). Novartis already has a separate discount scheme in place for Lucentis. The size of the discounts offered on both drugs is commercially confidential. ... Full Story | Top |
Quit-smoking treatments safe, effective: review Thursday, May 30, 2013 04:14 PM PDT By Andrew M. Seaman NEW YORK (Reuters Health) - Popular smoking cessation treatments - such as nicotine replacements and antidepressants - improve people's chances of kicking the habit without much risk, according to a review of past research. "It seems very clear that medications can help. They're not the magic bullet but you do improve your chances of quitting - generally - if you try them. And as far as we can tell, they're safe to use," said Kate Cahill, who led the study. ... Full Story | Top |
"Weak mayor" system keeps Toronto ticking through crack controversy Thursday, May 30, 2013 04:09 PM PDT | Top |
International court tells El Salvador to allow abortion of deformed fetus Thursday, May 30, 2013 03:56 PM PDT | Top |
Double dose of Tamiflu proves no better in severe flu Thursday, May 30, 2013 03:45 PM PDT | Top |
Toronto mayor vows to run again despite crack scandal, staff exodus Thursday, May 30, 2013 02:54 PM PDT | Top |
FDA denies approval to Endo's testosterone drug again Thursday, May 30, 2013 02:45 PM PDT (Reuters) - The Food and Drug Administration has for the third time refused approval to Endo Health Solutions Inc's injectable testosterone drug Aveed, pressing for a still better plan to manage the risks associated with the drug. The denial comes as no surprise after an advisory panel to the FDA overwhelmingly agreed in April that Endo's proposed plan for managing the risks associated with the drug was insufficient. Testosterone, a hormone produced in the testicles, is responsible for maintaining muscle bulk, bone growth and sexual function. ... Full Story | Top |
Some common prescriptions linked to impotence Thursday, May 30, 2013 01:12 PM PDT By Kerry Grens NEW YORK (Reuters Health) - Tranquilizers known as benzodiazepines and certain older antidepressants are linked with a greater chance of having erectile dysfunction (ED), according to a new survey. "Definitely it confirms the tricyclics (antidepressants)" are tied to ED, said Dr. Richard Balon, a psychiatry professor at Wayne State University School of Medicine. Contrary to some other studies, however, the research did not find any increased risk of ED among men taking blood-pressure medications. "I don't know what to make of this," said Balon, who was not part of the study. ... Full Story | Top |
Japanese drugmakers open 'libraries' in $100 million health project Thursday, May 30, 2013 12:13 PM PDT LONDON (Reuters) - Five top Japanese drug companies are to open their "libraries" of experimental compounds to scrutiny by scientists hunting new treatments for malaria, tuberculosis and other diseases affecting the world's poor. The initiative, announced on Thursday, is the first project under a new $100 million partnership between the drugmakers, the Japanese government and the Bill & Melinda Gates Foundation to fund research into neglected tropical diseases. ... Full Story | Top |
No science behind blood-type diets Thursday, May 30, 2013 11:39 AM PDT By Kathryn Doyle NEW YORK (Reuters Health) - They are a fad that refuses to fade, but no solid evidence exists to show whether or not eating plans tailored to ABO blood types promote health, say Belgian researchers who tried their best to find some. After sifting through the scientific literature, researchers identified just one indirectly related study - it looked at the effects of low-fat diets on cholesterol levels in people with different blood types - and even that one was weak, they concluded. ... Full Story | Top |
Could shedding extra pounds improve psoriasis? Thursday, May 30, 2013 09:34 AM PDT By Genevra Pittman NEW YORK (Reuters Health) - Losing weight may ease psoriasis and improve quality of life for some overweight people with the chronic skin disease, new research from Denmark suggests. But the trial may have been too small to fully flesh out that link, and researchers said future studies will have to follow larger groups of patients for more time to make definitive conclusions. "The results, I would say, are promising," said Dr. Joel Gelfand, a dermatologist from the University of Pennsylvania Perelman School of Medicine in Philadelphia. ... Full Story | Top |
|
No comments:
Post a Comment